News

Abraxis’ doxorubicin injection is the generic equivalent of Adriamycin PFS which is owned by Bedford Laboratories, a division of Boehringer Ingelheim. According to IMS, sales in 2006 of

Primary systemic light chain (AL) amyloidosis occurs when plasma cells in bone marrow produce proteins that misfold and deposit in tissues, leading to organ failure and death. Between

The FDA questioned how Advair 500/50 compared to the currently approved 250/50 strength in order to allow for appropriate dosing recommendations. GSK says it will be meeting with

The combination of chemotherapy and Avastin (bevacizumab) has been shown to increase survival in patients with metastatic colorectal and non-small-cell lung cancer, but some previous studies suggest these

Two patient advocacy groups have sued the FDA, the body in charge of drug approval which can involve years of testing. The groups are seeking access for terminally

SkyePharma says further discussions will be held over the coming weeks with the FDA to agree the scope of any additional clinical work. Undertaking this work could result

The company said that the positive results demonstrated the ability of Phosphagenics’s TPM technology to deliver insulin into the bloodstream in a non-invasive manner without causing any adverse

Neuromed said that the drug, MK-6721, does not demonstrate the ideal pharmaceutical characteristics considered necessary to advance the compound further in development. However, a joint research collaboration will

The amended agreements restructure the agreements originally signed in 2001, and are based upon the letter of intent signed in January 2006. Under the terms of the restated